Dose painting for re-irradiation of head and neck cancer. 2018

Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
a Department of Oncology , Oslo University Hospital , Oslo , Norway.

BACKGROUND For patients with recurrent or second primary disease, re-irradiation can be challenging due to overlap with previously irradiated volumes. Dose painting may be attractive for these patients, as the focus is on delivering maximal dose to areas of high tumor activity. Here, we compare dose painting by contours (DPBC) treatment plans based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) with conventional plans. METHODS We included 10 patients with recurrent or second primary head and neck cancer (HNC) eligible for re-irradiation. Our conventional re-irradiation regimen is hyperfractionated radiotherapy 1.5 Gy twice daily over 4 weeks, giving a total dose of 60 Gy. For DPBC, we defined two prescription volumes, PV33 and PV66, corresponding to 33 and 66% of the highest FDG uptake in the tumor. The clinical target volume (CTV) prescription dose was 60 Gy, PV33; 65-67 Gy and PV66; 70-73 Gy. The DPBC plan is to be given the first 20 fractions and the conventional plan the last 20 fractions. Dose to organs at risk (OARs) were compared for DPBC and conventional treatment. By summation of the initial curative plan and the re-irradiation plan, we also evaluated differences in dose to the 2 ccm hot spot (D2cc). RESULTS We achieved DPBC plans with adequate target coverage for all 10 patients. There were no significant differences in OAR doses between the standard plans and the DPBC plans (p=.7). Summation of the initial curative plan and the re-irradiation plan showed that the median D2cc increased from 130 Gy (range 113-132 Gy; conventional) to 140 Gy (range 115-145 Gy; DPBC). CONCLUSIONS Our proposed DPBC could be straightforwardly implemented and all plans met the objectives. Re-irradiation of HNC with DPBC may increase tumor control without more side effects compared to conventional radiotherapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D011880 Radiotherapy Planning, Computer-Assisted Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy. Computer-Assisted Radiotherapy Planning,Dosimetry Calculations, Computer-Assisted,Planning, Computer-Assisted Radiotherapy,Calculation, Computer-Assisted Dosimetry,Calculations, Computer-Assisted Dosimetry,Computer Assisted Radiotherapy Planning,Computer-Assisted Dosimetry Calculation,Computer-Assisted Dosimetry Calculations,Dosimetry Calculation, Computer-Assisted,Dosimetry Calculations, Computer Assisted,Planning, Computer Assisted Radiotherapy,Radiotherapy Planning, Computer Assisted
D005240 Feasibility Studies Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project. Feasibility Study,Studies, Feasibility,Study, Feasibility
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069475 Re-Irradiation Treatment in which a repeat course of RADIOTHERAPY is administered. Re Irradiation,Reirradiation
D000077195 Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer. HNSCC,Head And Neck Squamous Cell Carcinomas,Hypopharyngeal Squamous Cell Carcinoma,Laryngeal Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma,Oral Squamous Cell Carcinoma,Oral Squamous Cell Carcinomas,Oral Tongue Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma,Squamous Cell Carcinoma of Larynx,Squamous Cell Carcinoma of the Larynx,Squamous Cell Carcinoma of the Mouth,Squamous Cell Carcinoma of the Nasal Cavity,Carcinoma, Squamous Cell of Head and Neck,Head and Neck Squamous Cell Carcinoma,Squamous Cell Carcinoma of the Head and Neck,Squamous Cell Carcinoma, Head And Neck

Related Publications

Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
July 2011, International journal of radiation oncology, biology, physics,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
February 2022, Acta oncologica (Stockholm, Sweden),
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
January 2002, American journal of otolaryngology,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
July 2007, International journal of radiation oncology, biology, physics,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
September 2010, Anticancer research,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
May 2020, Acta oncologica (Stockholm, Sweden),
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
February 2018, Acta oncologica (Stockholm, Sweden),
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
December 2021, Radiation oncology journal,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
June 2012, Medical physics,
Torleiv Skjøtskift, and Morten E Evensen, and Torbjørn Furre, and Jon M Moan, and Cecilie D Amdal, and Trond V Bogsrud, and Eirik Malinen, and Einar Dale
November 2019, Oral oncology,
Copied contents to your clipboard!